Pipeline
Inventprise platform technologies support a robust pipeline of novel vaccines with the potential to unlock large market opportunities with significant unmet medical needs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Registration
IVT PCV-25* – Adult
Lead Candidate 25-valent Pneumococcal Conjugate
IVT PCV-25* – Infant
Lead Candidate 25-valent Pneumococcal Conjugate
IVT GBS-06*
Hexavalent Group B Streptococcal Vaccine
IVT Shigella-04
Quadrivalent Shigella Vaccine
IVT Klebsiella*
Klebsiella Vaccine
IVT D-MAP
Dissolvable Micro Array Patch
mRNA RSV
Respiratory Syncytial Virus mRNA Vaccine
* Developed with the PEG Linker Proprietary Platform
Learn More About Our Pipeline Programs
IVT PCV-25: Pneumococcal Conjugate Vaccine
Our high-valent pneumococcal conjugate vaccine, IVT PCV-25, is currently in development for both pediatric and adult populations globally and are both in Phase 2 clinical trial.
IVT PCV-25, leverages the Inventprise proprietary conjugation technology platform to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by children. Each one of these serotypes has been carefully evaluated and determined to be critical for the protection of children under the age of 5 regardless of the country in which they live.
The World Health Organization lists pneumonia as the leading cause of infectious disease death in children globally causing 14% of deaths under age 5, and 22% of deaths aged 1-5 years, with S. pneumonia as the most common pathogen. It also estimates more than 400,000 deaths in 2017 due to pneumococcal lower respiratory infection in >70-year-olds globally, of which nearly half were in lower- and middle-income countries, and highest in sub-Saharan Africa. While pneumococcal infections bacteremia and meningitis are less common than pneumonia, they are often more severe, with fatality rates reaching up to 60% among the elderly.1
IVT PCV-25 will be indicated for immunization for the prevention of pneumococcal disease and otitis media.
The value of the pneumococcal vaccines market is expected to grow from USD $8 Billion in 2023 to USD $14.78 Billion by 2034, reflecting an annual growth rate (CAGR) of 5.2% throughout the forecast period.2
1Centers for Disease Control and Prevention “Health and Economic Benefits of Routine Childhood Immunization in the Era of the Vaccines for Children’s Program – United States, 1994-2023”
2Source: Prophecy Market Insight as reported by Global Newswire.
IVT GBS-06: Group B Streptococcal Vaccine
Inventprise is developing IVT GBS-06, a novel group B streptococcus (GBS) hexavalent conjugate vaccine candidate for maternal immunization. Currently there is no vaccine to prevent GBS, a leading cause of sepsis and meningitis in neonates and young infants and a significant cause of stillbirth. GBS-06 leverages the Inventprise proprietary conjugation technology platform and is supported by funding from the Bill & Melinda Gates Foundation.
Globally, GBS is linked to more than half a million preterm births annually, resulting in nearly 100,000 newborn deaths and at least 46,000 stillbirths. In addition, more than 40,000 babies suffer from long-term neurological damage worldwide each year.3 Disease burden is highest in sub-Saharan Africa (with 54% of estimated cases and 65% of stillbirths and infant deaths) and South Asia. Current practice involves the use of prophylactic antibiotics given to birthing women, which has resulted in the emergence of wide-spread antibiotic resistance and may impact neonatal development.
IVT GBS-06 covers serotypes Ia, Ib, II, III, V and VII, potentially offering protection against 99% of GBS serotypes causing stillbirth, 98% of serotypes causing early onset disease (EOD), and 99% of serotypes causing late onset disease (LOD).
3World Health Organization (WHO) article: Urgent need for vaccine to prevent deadly Group B streptococcus
IVT Shigella-04: Shigella Vaccine
Inventprise is developing IVT Shigella-04, a quadrivalent conjugate vaccine, which aims to reduce morbidity and mortality from shigellosis, and might also have an indirect effect on reducing the use of antibiotics and consequent emergence of antimicrobial resistance (AMR). The World Health Organization has identified Shigella as a priority disease for which vaccines are urgently needed, considering the potential for herd immunity and protection from all-cause diarrhea. IVT Shigella-04 is supported by funding from the Bill & Melinda Gates Foundation.
Shigella bacteria cause an infection called shigellosis, with symptoms such as diarrhea (sometimes bloody), fever, and stomach cramps. Each year, it is estimated to cause at least 80 million cases of bloody diarrhea and 700,000 deaths. Almost all (99%) Shigella infections occur in children in low- and middle-income countries (LMICs), and the majority of cases (~70%), and of deaths (~60%), occur among children less than five years of age.4 Shigella is also a leading cause of diarrhea, with or without dysentery, in people older than five years of age, with an estimated 270 million episodes occurring annually among all ages5.
The development of a Shigella vaccine is an important goal for public health, considering the potential for herd immunity and protection from all-cause diarrhea.
4 Bagamian, KH., Anderson, K., Blohm, G., Scheele, S. Shigella and childhood stunting: Evidence, gaps and future research directions, PLOS Neglected Tropical Diseases, 2023 Sep 12; Libby TE et al. Consequences of Shigella infection in young children: a systematic review, Int. J Infect. Dis. 2023
5Troeger C, Blacker BF, et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhea: the Global Burden of Disease Study 1990–2016
IVT Klebsiella: Klebsiella Vaccine
Inventprise is currently developing a Klebsiella vaccine which, if effective, has the potential to reduce neonatal mortality from bacterial infections caused by Klebsiella pneumoniae. A vaccine could also reduce the use of antibiotics, especially in patients with chronic obstructive pulmonary disease (COPD), and decrease the emergence of antimicrobial resistance (AMR). IVT-Klebsiella leverages the Inventprise proprietary conjugation technology platform.
Klebsiella pneumoniae is a Gram-negative bacterium that causes bacterial infections and is a leading cause of hospital acquired infections (HAI). The infection results in symptoms such as pneumonia, meningitis, wound infections, and sepsis. Since 2013, Klebsiella has been listed as an urgent threat on the CDC Antibiotic Resistance watch list, and Klebsiella pneumoniae is listed as one of the organisms currently posing the worst threat to public health worldwide by the World Health Organization. It has been associated with 789,903 deaths globally in 2019, and accounts for 81 % of antimicrobial resistance (AMR) associated deaths.
The Global Burden of Diseases, Injuries, and Risk Factors study 2019 (GBD 2019) determined Klebsiella to be the leading cause of neonatal infectious deaths in LMICs, causing 129,151 deaths in 2019, with 87 % of these deaths being AMR related. There is no vaccine currently available on the market.
IVT D-MAP: Microneedle Patch
Dissolvable Microneedle Array Patches (D-MAPs), also referred to as microneedle patches, are a novel vaccine delivery method that has the potential to overcome barriers to vaccine delivery in LMICs. They are pain-free, easy to use, small in size (1 cm2) with a small storage footprint and could be thermostable, eliminating cold-chain requirements. Microneedle patches have been used in the health field for drugs and therapeutics, and are currently in development for vaccines with benefits ranging from ease of administration and increased thermostability, to improved drug delivery. IVT D-MAP has the potential to include multiple antigens on one patch.
Inventprise is developing a novel D-MAP technology with the potential to tackle vaccine delivery challenges facing current vaccine presentations and storage. The current D-MAP candidate has the ability to include multiple antigens in one patch.
IVT mRNA Vaccine Platform: RSV Vaccine
Inventprise is developing a new platform where any protein-expressing gene (antigen) can be cloned into an optimized plasmid to express high levels of messenger RNA (mRNA). These mRNAs are encapsulated into lipid nanoparticles (LNPs) to deliver the mRNA to muscle cells for expression of the protein/ antigen in humans. The antigen is recognized by the immune system as a foreign molecule, thus inducing immunity against any protein coding gene expressed in this form.
As part of this new platform, Inventprise is developing an mRNA vaccine to address the burden of respiratory syncytial virus (RSV), the most common cause of acute lower respiratory infection in young children.
We are developing this platform in a GMP setting, allowing us to quickly respond to new emerging infectious diseases or pandemics affecting any country in the world.